本帖最后由 老马 于 2013-3-13 13:43 编辑
R0 L$ T0 T# t/ k E9 ^
$ q6 A' _) O" ~5 S0 W! g6 o! d健择（吉西他滨）+顺铂+阿瓦斯汀( a9 c% f0 p% G8 P
Gemzar +Cisplatin + Avastin* T! U1 a: j$ ~* E3 e
http://annonc.oxfordjournals.org/content/21/9/1804.full
1 j1 p- {% ^' `, A u6 ROverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
9 h: n6 U! F8 _0 Y. SPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, v: H) l( s1 T# w0 x& H7 V5 aResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. # a3 Y4 Z* r2 @- X7 R' \ K8 G9 c
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 898)
1 B$ Y6 S; Z" ~& W$ v) V
华为网盘附件：
- W, O9 v$ O0 b* Y【华为网盘】ava.JPG1 B9 O2 E# E4 Q! F
|
显身卡
